Your browser doesn't support javascript.
loading
Management of advanced prostate cancer in the Asia-Pacific region: Summary of the Asia-Pacific Advanced Prostate Cancer Consensus Conference 2023.
Chiong, Edmund; Murphy, Declan G; Buchan, Nicholas; Chen, Kenneth; Chen, Sarah S; Chua, Melvin L K; Hamid, Agus Rizal; Kanesvaran, Ravindran; Khochikar, Makarand; Letran, Jason; Lojanapiwat, Bannakij; Mallik, Indranil; Ng, Chee Fai; Ong, Teng Aik; Poon, Darren M C; Pu, Yeong-Shiau; Saad, Marniza; Schubach, Kathryn; Takahara, Kiyoshi; Tey, Jeremy; Thang, Sue-Ping; Toh, Poh Choo; Türkeri, Levent; Vinh, Nguyen Tuan; Williams, Scott; Ye, Dingwei; Davis, Ian D.
Afiliação
  • Chiong E; Department of Urology, National University Hospital, and Department of Surgery, National University of Singapore, Singapore, Singapore.
  • Murphy DG; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Buchan N; Department of Urology, Christchurch Public Hospital, Christchurch, New Zealand.
  • Chen K; Monash University, Melbourne, Australia, Eastern Health, Melbourne, Australia.
  • Chen SS; Department of Urology, Singapore General Hospital, Singapore, Singapore.
  • Chua MLK; Department of Nursing, Tan Tock Seng Hospital, Singapore, Singapore.
  • Hamid AR; Department of Head Neck and Thoracic Cancers, Division of Radiation Oncology, National Cancer Centre Singapore, Singapore, Singapore.
  • Kanesvaran R; Department of Urology, Faculty of Medicine Universitas Indonesia - CiptoMangunkusumo Hospital, Jakarta, Indonesia.
  • Khochikar M; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.
  • Letran J; Department of Urology/Uro-oncology, Ushakal Abhinav Institute of Medical Sciences, Sangli, India.
  • Lojanapiwat B; Department of Urology, Chinese General Hospital and Medical Center, Manila, Philippines.
  • Mallik I; Department of Surgery, Chiang Mai University, Chiang Mai, Thailand.
  • Ng CF; Department of Radiation Oncology, Tata Medical Center, Kolkata, India.
  • Ong TA; SH Ho Urology Centre, The Chinese University of Hong Kong, Hong Kong, China.
  • Poon DMC; Department of Surgery, Universiti Malaya, Kuala Lumpur, Malaysia.
  • Pu YS; Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China.
  • Saad M; Department of Urology, National Taiwan University College of Medicine and Hospital, Taipei, Taiwan.
  • Schubach K; Department of Clinical Oncology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
  • Takahara K; Monash University, Melbourne, Australia, Eastern Health, Melbourne, Australia.
  • Tey J; Australian and New Zealand Urology Nurses (ANZUNS), Melbourne, Australia.
  • Thang SP; Department of Urology, Fujita Health University, Toyoake, Japan.
  • Toh PC; Department of Radiation Oncology, National University Cancer Institute Singapore, Singapore, Singapore.
  • Türkeri L; Department of Nuclear Medicine and Molecular Imaging, Singapore General Hospital, Singapore, Singapore.
  • Vinh NT; Department of Urology, National University Hospital, and Department of Surgery, National University of Singapore, Singapore, Singapore.
  • Williams S; Department of Urology, Altunizade Hospital, Acibadem M.A. Aydinlar University, Istanbul, Turkey.
  • Ye D; Department of Urology, Binh Dan Hospital, Ho Chi Minh City, Vietnam.
  • Davis ID; Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
Asia Pac J Clin Oncol ; 20(4): 481-490, 2024 Aug.
Article em En | MEDLINE | ID: mdl-38628049
ABSTRACT

AIM:

The aim of the third Asia-Pacific Advanced Prostate Cancer Consensus Conference (APAC APCCC 2023) was to discuss the application in the Asia-Pacific (APAC) region of consensus statements from the 4th Advanced Prostate Cancer Consensus Conference (APCCC 2022).

METHODS:

The one-day meeting in July 2023 brought together 27 experts from 14 APAC countries. The meeting covered five topics (1) Intermediate- and high-risk and locally advanced prostate cancer; (2) Management of newly diagnosed metastatic hormone-sensitive prostate cancer; (3) Management of non-metastatic castration-resistant prostate cancer; (4) Homologous recombination repair mutation testing; (5) Management of metastatic castration-resistant prostate cancer. Pre- and post-symposium polling gathered APAC-specific responses to APCCC consensus questions and insights on current practices and challenges in the APAC region.

RESULTS:

APAC APCCC highlights APAC-specific considerations in an evolving landscape of diagnostic technologies and treatment innovations for advanced prostate cancer. While new technologies are available in the region, cost and reimbursement continue to influence practice significantly. Individual patient considerations, including the impact of chemophobia on Asian patients, also influence decision-making.

CONCLUSION:

The use of next-generation imaging, genetic testing, and new treatment combinations is increasing the complexity and duration of prostate cancer management. Familiarity with new diagnostic and treatment options is growing in the APAC region. Insights highlight the continued importance of a multidisciplinary approach that includes nuclear medicine, genetic counseling, and quality-of-life expertise. The APAC APCCC meeting provides an important opportunity to share practice and identify APAC-specific issues and considerations in areas of low evidence where clinical experience is growing.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Humans / Male País/Região como assunto: Asia Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Humans / Male País/Região como assunto: Asia Idioma: En Ano de publicação: 2024 Tipo de documento: Article